There are 79 papers on CHEK2 in aging research: 1 trial and 24 observational studies in people, 28 in animals, 16 in cells, 9 reviews. The newest story, Oct 13, 2026: “Blood mutations skew pooled human cancer mutation data”.
CHEK2 shortens lifespan and promotes senescence in mouse models across independent labs, although a study in telomere-dysfunctional mice finds no clear lifespan effect. One group links CHEK2 predicted loss-of-function variants with higher cancer risk in humans. The National Natural Science Foundation of China funds much of this work; Eli Lilly also provides funding.
31 findings in 19 papers from 2003 to 2026, 4 of them since April 2026
The findings reach people, from one lab or study; independent labs found the same change in mice. 14 independent labs in 8 countries.
“the presence of at least one CHEK2 pLoF variant was associated with increased odds of diagnosis with 14 different cancers (odds ratio [OR] range: 1.34-3.21).”
Mice: replicated by independent labs. Cells and humans: a single group. Worms or flies: nothing yet.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
Includes the processes named after it and trials of drugs aimed at it.
14 independent labs in 8 countries
1 finding against
Funders: National Natural Science Foundation of China and others
5 of 31 findings with company ties
Human trial1
Humans24
Animals28
Cells16
In silico1
Interventions
1
Exercise
↑upin mice1
1 study
Exercise increases CHEK2 in mice (immediately after treadmill running (TP1) vs baseline and 1 h post).
“greater expression of DNA-repair and -response genes (Chk2 and Ku80)”
Animalsimmediately after treadmill running (TP1) vs baseline and 1 h postcardiac muscle
CHEK2 decreases stem cell maintenance in mice (shown by deletion in Bmi1-/- mice).
“In addition, it boosted proliferation of bone marrow mesenchymal stem cells (BM-MSCs) that derived from mandible through blocking the DNA damage response pathway.”
“Chk2 deletion in Pthrp KI mice can somewhat rescue defects in osteoblastic bone formation and skeletal growth by enhancing endochondral bone formation and osteogenesis.”
Colorectal, breast, ovarian and prostate cancer risk
↔no changein humans1
1 study
CHEK2 was not clearly linked with colorectal, breast, ovarian and prostate cancer risk in humans (CHEK2 del5395 carriers in the Latvian population) (No statistically significant associations; p = 0.39–1.00 across groups).
“does not have a direct impact on genetic predisposition toward colorectal, breast, ovarian and prostate cancer.”
HumansCHEK2 del5395 carriers in the Latvian population
CHEK2 is linked with a higher risk of cancer risk in humans (presence of at least one CHEK2 pLoF variant) (OR range: 1.34-3.21).
“the presence of at least one CHEK2 pLoF variant was associated with increased odds of diagnosis with 14 different cancers (odds ratio [OR] range: 1.34-3.21).”
CHEK2 is associated with recurring founder variant in Israel in humans (c.592+3A>T variant; PMS2 (c.943C>T) and CDKN2A (c.176T>G) variants reported alongside).
“CHEK2 (c.592+3A>T), PMS2 (c.943C>T), and CDKN2A (c.176T>G) were identified as potentially recurring founder variants.”
CHEK2 is associated with age at natural menopause in humans (CHEK2 c.1100delC heterozygotes compared with non-carriers) (1.5–2.2 years later natural menopause).
“CHEK2 c.1100delC is associated with 1.5-2.2 years later ANM compared with non-carriers”
HumansCHEK2 c.1100delC heterozygotes compared with non-carriersfemales
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·
CHEK2 is associated with senescence in human alveolar epithelial cells and idiopathic pulmonary fibrosis in silico. A preprint reports increased CHEK2 with ovarian aging in mice and human ovarian somatic cells; a human study links CHEK2 pLoF variants to increased cancer risk. Three independent labs report distinct findings, without replication of the same change.
For one gene involved in DNA modification, 52.8% of patients flagged as carrying a mutation had no tumor-derived mutation in that gene.For one gene involved in DNA modification, 52.8% of patients flagged as carrying a mutation had no tumor-derived mutation in that gene.
A multi-omic analysis shows that defective luteal resolution and CHK2-driven inflammation drive ovarian aging, but drug inhibition restores oocyte maturation.A multi-omic analysis shows that defective luteal resolution and CHK2-driven inflammation drive ovarian aging, but drug inhibition restores oocyte maturation.